Acura Pharmaceuticals announced multiple actions with Abuse Deterrent Pharma to bolster liquidity and progress its LIMITx program. The company received $400,000 in additional loan advances, bringing the secured note’s principal to $10.69 million at 5.25% interest as of June 24, 2026, and extended the note’s maturity to December 31, 2026. Acura also amended its LTX-03 license to extend the FDA NDA acceptance deadline to December 31, 2026, with AD Pharma retaining termination rights and potential ownership of LTX-03 IP if the deadline is missed. Additionally, the AD Pharma warrant expiration moved to December 31, 2026, aligning with the note.
Agreement 1: Acura Pharmaceuticals Receives $400K in Additional AD Pharma Loans; Note Balance Now $10.7M at 5.25%
- Agreement type: Secured promissory note advances under existing note
- Counterparty: Abuse Deterrent Pharma
- Signed / Effective: Jun 24 2026 / same
- Duration / Termination: Matures Dec 31 2026
- Reason: Provide working capital for operations
Agreement 2: Acura Pharmaceuticals and AD Pharma Extend LTX-03 NDA Acceptance Deadline to Dec. 31, 2026
- Agreement type: Amendment to License, Development and Commercialization Agreement for LTX-03
- Counterparty: Abuse Deterrent Pharma
- Signed / Effective: Jun 29 2026 / Jun 15 2026
- Duration / Termination: At will
- Reason: Extend NDA acceptance deadline for LTX-03
Agreement 3: Acura Pharmaceuticals Extends AD Pharma Secured Note Maturity to Dec. 31, 2026
- Agreement type: Amendment to Secured Promissory Note
- Counterparty: Abuse Deterrent Pharma
- Signed / Effective: Jun 29 2026 / Jun 15 2026
- Duration / Termination: Matures Dec 31 2026
- Reason: Extend debt maturity to year-end
Agreement 4: Acura Pharmaceuticals Extends AD Pharma Warrant Expiration to Dec. 31, 2026
- Agreement type: Amendment to Common Stock Purchase Warrant
- Counterparty: Abuse Deterrent Pharma
- Signed / Effective: Jun 15 2026 / same
- Duration / Termination: Expires Dec 31 2026
- Reason: Align warrant expiry with note maturity
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.